AI vs. Manual Literature Review: Which One Ensures Better Compliance?
- Chailtali Gaikwad
- May 23, 2025
- 4 min read
In the high-stakes world of pharmacovigilance (PV), literature reviews play a critical role in monitoring the safety profile of drugs and ensuring regulatory compliance. Regulatory agencies such as the EMA and FDA mandate that marketing authorization holders (MAHs) continuously review scientific literature for adverse drug reactions (ADRs), case reports, and emerging safety signals. Historically, these reviews have been conducted manually by trained professionals. However, with the advent of artificial intelligence (AI), especially natural language processing (NLP) and machine learning (ML), the literature review landscape is evolving rapidly.
But this evolution prompts a pressing question: Does AI offer better compliance assurance than manual literature review methods, or does the human touch still reign supreme? In this blog, we delve into the pros, cons, and comparative compliance outcomes of both approaches.
Understanding Literature Review in Pharmacovigilance
A literature review in PV involves systematically searching, screening, and analyzing scientific publications for information relevant to drug safety. This includes:
Identifying individual case safety reports (ICSRs)
Tracking emerging adverse drug reactions
Assessing benefit-risk profiles
Monitoring effectiveness of risk minimization measures
The goal is not just to stay informed but to ensure timely regulatory submissions, maintain compliance with Good Pharmacovigilance Practices (GVP), and uphold patient safety.
Manual Literature Review: The Traditional Approach
Strengths
Human Judgment: Trained professionals can interpret nuanced clinical data, understand contextual relevance, and identify subtle safety signals that might not be explicitly stated.
Regulatory Familiarity: Manual reviewers often have a deep understanding of regulatory requirements and can tailor the review process accordingly.
Cross-Referencing Capabilities: Humans can integrate data from multiple sources, assess causality, and exercise clinical discretion.
Challenges
Time-Intensive: Reviewing hundreds or thousands of articles weekly is not scalable.
Prone to Human Error: Fatigue, oversight, and subjectivity can lead to missed signals or misinterpretation.
Costly: The process demands significant investment in skilled manpower and infrastructure.
Inconsistency: Different reviewers may apply varying interpretations, which can affect standardization and reproducibility.
AI-Driven Literature Review: The Modern Solution
How It Works
AI-powered platforms utilize NLP, ML algorithms, and rule-based systems to automate:
Search and retrieval of relevant literature
De-duplication of articles
Identification and extraction of ICSRs and key safety terms
Signal detection based on predefined rules
Generation of draft reports for review
Strengths
Speed and Scalability: AI systems can analyze thousands of documents in a fraction of the time humans take.
Consistency: Once trained, AI applies the same rules uniformly across datasets.
Enhanced Sensitivity: AI can pick up patterns and associations that may be too subtle or voluminous for human detection.
24/7 Operation: No downtime, fatigue, or productivity drop-offs.
Limitations
Initial Training Requirement: AI systems need high-quality, annotated data to learn effectively.
Interpretation Gaps: Complex contextual judgment, sarcasm, or ambiguous phrasing can trip up even sophisticated AI models.
Regulatory Acceptance: While gaining traction, some regulators may still require human oversight to validate AI-derived outputs.
Compliance: The Core Criterion
What Does Compliance Entail?
In pharmacovigilance, compliance means:
Meeting regulatory timelines for literature screening and reporting
Accurately identifying and processing all reportable cases
Documenting decisions and justifications for inclusion or exclusion
Ensuring audit-readiness and traceability
Non-compliance can lead to warning letters, fines, reputational damage, and even product withdrawal.
Manual Review and Compliance
While manual review has traditionally met compliance requirements, it’s increasingly challenged by:
Rising publication volume
Expanding scope of global regulatory expectations
Resource constraints in smaller PV teams
Even well-resourced teams can falter in keeping pace, risking delays in ICSR submissions or signal detection.
AI and Compliance
AI-driven reviews align well with compliance imperatives by:
Accelerating timelines: Faster processing ensures timely reporting.
Minimizing missed cases: Improved sensitivity reduces the risk of oversight.
Enhancing audit-readiness: Automated systems maintain detailed logs of searches, filters, and processing decisions.
Supporting global compliance: Multilingual processing enables monitoring of regional journals and non-English publications.
Still, to fully ensure compliance, AI systems must be:
Validated according to GxP standards
Regularly audited and fine-tuned
Used under human supervision for final decision-making
Hybrid Approach: The Best of Both Worlds?
Rather than pitting AI against humans, the most compliant systems today use a hybrid model where AI handles the heavy lifting, and experts apply clinical judgment.
Example Workflow:
AI filters and ranks articles based on relevance.
AI extracts potential ICSRs and flags unusual patterns.
Human reviewers validate, interpret, and submit the final reports.
This approach ensures:
Speed and consistency from AI
Contextual understanding from human experts
Regulatory confidence through traceability and oversight
Real-World Evidence: AI in Action
Several life sciences companies and PV vendors have reported significant compliance improvements after adopting AI, including:
Reduction in review cycle time by 60–80%
Improved ICSR detection rates
Fewer findings in regulatory audits
Higher coverage of global literature sources
A 2023 study published in Drug Safety found that AI-enabled literature monitoring tools achieved higher recall and precision in ICSR identification compared to manual review teams, especially in high-volume therapeutic areas like oncology and cardiovascular disease.
Regulatory Perspectives on AI Use
Agencies like the EMA and MHRA have begun issuing guidance on the use of automation in PV. Key takeaways include:
AI can be used for screening and triage, but final case validation must involve qualified professionals.
Systems must be validated, traceable, and transparent.
Companies must demonstrate that AI use does not compromise data integrity or compliance.
In short, regulators are open to AI—as long as it’s used responsibly.
Key Considerations When Transitioning to AI
Vendor Selection: Choose partners with validated tools, domain expertise, and strong regulatory understanding.
Integration: Ensure seamless integration with your safety database and existing workflows.
Training & Change Management: Equip your team with training to interpret AI outputs and manage exceptions.
Ongoing Monitoring: Periodically assess AI performance against KPIs like recall, precision, and turnaround time.
Documentation: Maintain robust documentation to support audits and inspections.
Conclusion: Who Wins—AI or Manual Review?
When it comes to ensuring compliance, AI doesn’t replace human expertise—it enhances it. Purely manual reviews are no longer sustainable in today’s data-intensive landscape. On the other hand, unsupervised AI can’t yet match human intuition and judgment.
The most compliant and future-ready PV systems embrace a collaborative model, where AI serves as an intelligent assistant and humans provide oversight, clinical context, and regulatory stewardship.
So, who ensures better compliance? The answer is: Both—when used together.
By investing in AI-powered literature review tools and pairing them with skilled professionals, organizations can achieve faster, more accurate, and more compliant pharmacovigilance practices—ultimately contributing to better patient safety and regulatory harmony.
Comments